T-cell therapy for EBV-associated nasopharyngeal carcinoma: preparative lymphodepleting chemotherapy does not improve clinical results-Reference-Cited by-同舟云学术

T-cell therapy for EBV-associated nasopharyngeal carcinoma: preparative lymphodepleting chemotherapy does not improve clinical results

Published:2012-02 Issue:2 Volume:23 Page:435-441
ISSN:0923-7534
Container-title:Annals of Oncology
language:en
Short-container-title:Annals of Oncology

Author:

Secondino S.,Zecca M.,Licitra L.,Gurrado A.,Schiavetto I.,Bossi P.,Locati L.,Schiavo R.,Basso S.,Baldanti F.,Maccario R.,Locatelli F.,Siena S.,Pedrazzoli P.,Comoli P.

Funder

Associazione Italiana per la Ricerca sul Cancro

Ministero della Salute: Progetti Ricerca Oncologica

Progetti Ricerca Finalizzata

Regione Lombardia

Fondazione IRCCS Policlinico San Matteo, Progetti di Ricerca Corrente

Oncologia Ca’ Granda Onlus Fondazione

Publisher

Elsevier BV

Subject

Oncology,Hematology

Link

http://academic.oup.com/annonc/article-pdf/23/2/435/552080/mdr134.pdf

Reference36 articles.

1. Nasopharyngeal carcinoma;Chan;Ann Oncol,2002

2. Nasopharyngeal cancer: ESMO clinical recommendations for diagnosis, treatment and follow-up;Chan;Ann Oncol,2008

3. The additional value of chemotherapy to radiotherapy in locally advanced nasopharyngeal carcinoma: a meta-analysis of the published literature;Langendijk;J Clin Oncol,2004

4. Effectiveness of combined induction chemotherapy and radiotherapy in advanced nasopharyngeal carcinoma;Dimery;J Clin Oncol,1993

5. A phase II study of docetaxel and carboplatin as neoadjuvant therapy for nasopharyngeal carcinoma with early T status and advanced N status;Johnson;Cancer,2004

Cited by 59 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Gemcitabine, carboplatin, and Epstein Barr virus-specific autologous cytotoxic T lymphocytes for recurrent or metastatic nasopharyngeal carcinoma: VANCE, an international randomized Phase 3 trial;Annals of Oncology;2024-09

2. Stem cell memory EBV-specific T cells control EBV tumor growth and persist in vivo;Science Advances;2024-08-23

3. Leveraging oncovirus-derived antigen against the viral malignancies in adoptive cell therapies;Biomarker Research;2024-07-29

4. Geographic EBV variants confound disease-specific variant interpretation and predict variable immune therapy responses;Blood Advances;2024-07-12

5. Efficacy and Safety of Cell-based Immunotherapy in The Treatment of Recurrent or Metastatic Nasopharyngeal Carcinoma – A Systematic Review and Meta-analysis;Oral Oncology;2024-05